Diplomat Pharmacy (DPLO) Upgraded by ValuEngine to Buy

Diplomat Pharmacy (NYSE:DPLO) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other research firms also recently weighed in on DPLO. Zacks Investment Research downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. JPMorgan Chase & Co. raised Diplomat Pharmacy from a “neutral” rating to an “overweight” rating in a research report on Thursday, May 10th. Needham & Company LLC set a $28.00 price target on Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Leerink Swann set a $30.00 price target on Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, Barclays assumed coverage on Diplomat Pharmacy in a research report on Thursday, March 8th. They set an “overweight” rating and a $27.00 price target for the company. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $26.90.

Diplomat Pharmacy opened at $27.17 on Friday, according to Marketbeat. Diplomat Pharmacy has a 52-week low of $14.23 and a 52-week high of $27.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.88 and a quick ratio of 0.57. The company has a market cap of $1.96 billion, a P/E ratio of 32.35 and a beta of 1.33.



Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, May 7th. The company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.01). Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the previous year, the company posted $0.19 earnings per share. Diplomat Pharmacy’s revenue for the quarter was up 24.4% compared to the same quarter last year. sell-side analysts expect that Diplomat Pharmacy will post 0.92 earnings per share for the current year.

In other Diplomat Pharmacy news, Director Shawn Tomasello sold 1,680 shares of the firm’s stock in a transaction on Tuesday, June 5th. The stock was sold at an average price of $24.27, for a total transaction of $40,773.60. Following the completion of the sale, the director now owns 12,816 shares of the company’s stock, valued at approximately $311,044.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey G. Park sold 13,875 shares of the firm’s stock in a transaction on Wednesday, May 23rd. The shares were sold at an average price of $24.20, for a total value of $335,775.00. The disclosure for this sale can be found here. In the last three months, insiders sold 17,250 shares of company stock valued at $419,364. 24.70% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in Diplomat Pharmacy during the 1st quarter worth $104,000. Meadow Creek Investment Management LLC bought a new position in Diplomat Pharmacy during the 1st quarter worth $107,000. Glen Harbor Capital Management LLC bought a new position in Diplomat Pharmacy during the 1st quarter worth $129,000. Advisors Preferred LLC bought a new position in Diplomat Pharmacy during the 4th quarter worth $162,000. Finally, UBS Group AG increased its position in shares of Diplomat Pharmacy by 186.4% in the first quarter. UBS Group AG now owns 8,491 shares of the company’s stock worth $171,000 after purchasing an additional 5,526 shares during the period. 75.92% of the stock is owned by institutional investors and hedge funds.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply